Psolar is an 8-10 year registry study. A registry is an observational study that evaluates the status of a disease. This registry study will only include subjects who volunteer to take part. About 4000 infliximab-exposed subjects and 4000 additional patients receiving other Psoriasis medications/treatments (e.g. Etanercept, steroids, etc.) will take part in the registry study at about 450 centers in the U.S. The Registry does not require any study-specific testing, but may capture test information (e.g. laboratory tests, X-rays) that are collected as part of normal routine care for the registry program. Patient information will be collected at the enrollment visit and about every 6 months thereafter. Upon enrollment, the following information will be collected: demographics (e.g. gender, race, date of birth), medical history, family medical history, history of previous psoriasis treatments, current medications, how you receive infliximab or standard therapies and clinical follow-up, observations from your physical examinations, clinical disease status, Quality of life assessment (e.g. Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, EQ-5D Health Questionnaire Scale, Employment/Productivity Health Economic Questionnaire), current medications, and any adverse events/problems. During each six -month follow-up visit with the study doctor, information collected will include observations from physical examination, updates on clinical disease status, Quality of life assessments, medications and adverse events/problems.

No study agents will be administered in this registry. All patients will receive standard of care treatments prescribed by the patient's physician.